Magnus Medical

Magnus Medical is a neurotechnology company based in Burlingame, California, focused on developing advanced neuromodulation therapies for psychiatric conditions. The company's flagship product is built around SAINT, or Stanford Accelerated Intelligent Neuromodulation Therapy, a personalized transcranial magnetic stimulation protocol originally developed at Stanford University. What distinguishes SAINT from conventional TMS approaches is its use of functional MRI imaging to precisely identify each patient's individualized neural targets, allowing clinicians to deliver stimulation with significantly greater accuracy. The protocol is designed to compress a traditional multi-week TMS treatment course into a matter of days, offering a faster and potentially more effective path to antidepressant relief for patients with treatment-resistant depression.

Magnus Medical has established a strong early foothold in the competitive neuromodulation market, supported by a Series B funding round totaling 50 million dollars. The company's SAINT system received FDA Breakthrough Device designation, a recognition that underscores both the clinical urgency of the problem it addresses and the potential of its approach to outperform existing standard-of-care options. Clinical trials underpinning the technology have demonstrated rapid and substantial reductions in depression symptoms, with some studies reporting remission rates that far exceed those seen with traditional TMS or pharmacological treatments. These milestones have positioned Magnus Medical as one of the more clinically credible and commercially promising entrants in the brain stimulation space.

Magnus Medical represents a meaningful inflection point for the broader neurotech industry, demonstrating that personalized, imaging-guided neuromodulation can be translated from academic research into a scalable clinical product. By addressing treatment-resistant depression, a condition affecting millions of patients who have failed to respond to conventional therapies, the company is targeting one of the most underserved populations in psychiatry. Their work also signals a broader shift in the field toward precision neuromodulation, where individual neuroanatomy and connectivity data inform treatment rather than relying on generalized stimulation parameters. As interest in non-pharmacological mental health interventions continues to grow, Magnus Medical's approach may serve as a blueprint for next-generation therapies across a range of neurological and psychiatric disorders.